To reduce this risk, the control group will be offered support with the selection of patients with T2D and a very high risk of cardiovascular complications who are younger than 70 years of age, thereby possibly eligible for starting sodium-glucose transporter 2 inhibitors (SGLT2i) or glucagon-like peptide-1 (GLP1) medication. Here, GCG is linked to type 2 diabetes mellitus.